Every once in a while a company reaches out to me with some interesting news. When that happens, I try and pass it along to all of you. Today's post is something I feel bears further investigation, but it looks promising in its initial stages.
One of the most difficult areas to treat, from a periodontal standpoint, is furcation involvement. It seems that frequently once the furcation of a molar becomes periodontally compromised, there is little we can do to help stem the tide of the disease.
The study sited below is *very* small (only 3 subjects), but a positive result is still intriguing. I'm interested to see how this looks long term and with more results. I would say that at this point, it definitely bears more investigation. Long term, something like this (if it pans out) could be a great thing for patients. Especially as our medical system continues to improve and people are living longer, quality of life becomes extremely important. Being able to eat and stay well nourished is part of the quality of life. Periodontal health has a tremendous impact on overall systemic health and patients with periodontal disease aren't always good candidates for implant placement. That means helping those patients keep their natural teeth is critically important.
The Biotech company has large animal proof-of-concept results for its lead product, Ambrilux Dental Gel, in the setting of periodontal disease characterized by bone loss in the tooth furcation
Oral Biolife (OBL), a biotechnology company developing a first-of-its-kind dental treatment for humans and companion animals, today announced critical new developments of large animal data backing their lead product, Ambrilux Dental Gel.
Ambrilux Dental Gel has been shown to promote the regeneration of bone in the furcations of teeth in three Beagle dogs with induced periodontal disease(PD).
Radiographs were taken at baseline 28 days after the first application and 29 days after the 2nd application. The radiographs demonstrated that 100% (n=3) of animals treated with Ambrilux showed increased bone regeneration at both the 1st and second month post-treatment while only 33% (n=3)of control animals had detectable bone growth. The ability of Ambrilux to promote bone growth in the setting of periodontal disease in large animals provides key translatable data supporting the potential use in human disease.
There were no Adverse Events or other safety issues noted throughout the study. An adverse event is defined as any unexpected observation seen in dogs that is unfavorable and unintended and occurs after the use of an investigational veterinary product, regardless of the possible relationship to the product.
“This proof-of-concept marks a major milestone in our journey. It reinforces our confidence that Ambrilux Dental Gel has the potential to revolutionize how dental care is provided, offering a less invasive and more accessible option for patients," says Bill Breitenbach, CEO of Oral Biolife.”
With Periodontitis affecting nearly 20% of the global population, 47% of US adults, as well as costing an estimated yearly 54 billion USD in loss of productivity1, there is clearly an unmet need for an effective non-invasive solution to treat PD. OBL’s findings are a step towards a potential breakthrough in dental and oral health research.
“At OBL our mission has always been to find a way to provide Americans with access to non-invasive dental care,” says Stella Vnook, President of Oral Biolife. “We are pleased with these promising results and are excited to continue our research to further establish the safety and efficacy of the Ambrilux Dental Gel.”
About Oral Biolife Inc.
Oral Biolife is an innovative biotechnology company headquartered in Bethlehem, PA that utilizes the unique properties of biotechnology materials to develop groundbreaking, first-to-market products. Their lead asset, Ambrilux Dental Gel, via its unique ability to regenerate bone lost due to periodontal disease, represents a potential breakthrough for treating periodontal disease. For more information, please visit https://www.oralbiolife.com/ and on LinkedIn at https://www.linkedin.com/company/oralbiolife-inc/.
References:
Thornton-Evans G, Eke P, Wei L, Palmer A, Moeti R, Hutchins S, Borrell LN; Centers for Disease Control and Prevention (CDC). Periodontitis among adults aged ≥30 years - United States, 2009-2010. MMWR Suppl. 2013 Nov 22;62(3):129-35.åˇ
No comments:
Post a Comment